Literature DB >> 2932539

Neuropathological classification of Huntington's disease.

J P Vonsattel, R H Myers, T J Stevens, R J Ferrante, E D Bird, E P Richardson.   

Abstract

In postmortem brain specimens from 163 clinically diagnosed cases of Huntington's disease (HD) the striatum exhibited marked variation in the severity of neuropathological involvement. A system for grading this severity was established by macroscopic and microscopic criteria, resulting in five grades (0-4) designated in ascending order of severity. The grade correlates closely with the extent of clinical disability as assessed by a rating scale. In five cases of clinically diagnosed HD there were no discernible neuropathological abnormalities (grade 0), suggesting that the anatomical changes lag behind the development of clinical abnormalities. In eight cases, neuropathological changes could only be recognized microscopically (grade 1). The earliest changes were seen in the medial paraventricular portions of the caudate nucleus (CN), in the tail of the CN, and in the dorsal part of the putamen. Counts of neurons in the CN reveal that 50% are lost in grade 1 and that 95% are lost in grade 4; astrocytes are greatly increased in grades 2-4. These studies indicate that analyses of the CN in grade 4 would reflect mainly its astrocytic composition with a component of remote neurons projecting to the striatum. Because of the relative preservation of the lateral half of the head of the CN in grades 1-2, these regions would reflect early cellular and biochemical changes in HD.

Entities:  

Mesh:

Year:  1985        PMID: 2932539     DOI: 10.1097/00005072-198511000-00003

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  718 in total

Review 1.  Polyglutamine pathogenesis.

Authors:  C A Ross; J D Wood; G Schilling; M F Peters; F C Nucifora; J K Cooper; A H Sharp; R L Margolis; D R Borchelt
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

2.  From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington's disease.

Authors:  S W Davies; M Turmaine; B A Cozens; A S Raza; A Mahal; L Mangiarini; G P Bates
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

3.  Aggregation of truncated GST-HD exon 1 fusion proteins containing normal range and expanded glutamine repeats.

Authors:  B Hollenbach; E Scherzinger; K Schweiger; R Lurz; H Lehrach; E E Wanker
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

4.  Evidence for a recruitment and sequestration mechanism in Huntington's disease.

Authors:  E Preisinger; B M Jordan; A Kazantsev; D Housman
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 5.  Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease.

Authors:  J H Cha; A S Frey; S A Alsdorf; J A Kerner; C M Kosinski; L Mangiarini; J B Penney; S W Davies; G P Bates; A B Young
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 6.  Transgenic models of Huntington's disease.

Authors:  K Sathasivam; C Hobbs; L Mangiarini; A Mahal; M Turmaine; P Doherty; S W Davies; G P Bates
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

7.  Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.

Authors:  P H Reddy; V Charles; M Williams; G Miller; W O Whetsell; D A Tagle
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

8.  Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy.

Authors:  V Heiser; E Scherzinger; A Boeddrich; E Nordhoff; R Lurz; N Schugardt; H Lehrach; E E Wanker
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

9.  Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice.

Authors:  J A Bibb; Z Yan; P Svenningsson; G L Snyder; V A Pieribone; A Horiuchi; A C Nairn; A Messer; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

10.  The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription.

Authors:  J S Steffan; A Kazantsev; O Spasic-Boskovic; M Greenwald; Y Z Zhu; H Gohler; E E Wanker; G P Bates; D E Housman; L M Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.